Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

CyberAgent 4Q: A Strong Fiscal Year; Indicative of a Business Turnaround?

Hoya: Long-Term Prospects Seem Attractive Though Some Short-Term Weaknesses Exist

Hoya – MiyoSmart Extends Industry Leading Premium Product Strategy to Life Care

Shift 4Q: Growth Story Is Getting Stronger

M3: Medlive IPO Helped OP Surge in 1Q; Expect Earnings Weakness to Come Through in 2H

BayCurrent Consulting: Strong Earnings Momentum Continues

Gravity Works As WeWork Doesn't; Now Plan B

Bifurcated Chinese Express Market Developing

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

<a href="https://www.smartkarma.com/entities/m3-inc" target="_blank" data-smartkarma-citation="entities:13316:1" rel="noopener">M3 Inc (2413 JP)</a> reported its 2QFY03/2022 results on Wednesday (27th October) which saw revenues growing 29.6% YoY to JPY51.2bn while reported OP (including profit from Medlive IPO) for the quarter increased 194.1% YoY to JPY37.3bn. Excluding the impact from Medlive IPO, the adjusted OP grew 21.8% YoY to JPY15.4bn during the second quarter.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/237/973/original/image_42895307621635358784594.png?1635358786" class="editor-image img-responsive" data-smartkarma-image-id="237973"></figure>Source: Company disclosuresThe reported revenue for 2QFY03/2022 was 4.3% higher vs consensus revenue of JPY49.1bn while reported OP for the quarter was 8.5% higher vs consensus OP of JPY34.4bn.

M3 Inc (2413 JP) reported its 2QFY03/2022 results on Wednesday (27th October) which saw revenues growing 29.6% YoY to JPY51.2bn while reported OP (including profit from Medlive IPO) for the quarter increased 194.1% YoY to JPY37.3bn. Excluding the impact from Medlive IPO, the adjusted OP grew 21.8% YoY to JPY15.4bn during the second quarter.Source: Company disclosuresThe reported revenue for 2QFY03/2022 was 4.3% higher vs consensus revenue of JPY49.1bn while reported OP for the quarter was 8.5% higher vs consensus OP of JPY34.4bn.

M3: Strong 2Q Results but Earnings Growth Starts Decelerating